Open AccessDYSLIPIDEMIA: CONTRADICTIONS IN TREATMENT FROM THE POSITIONS OF NEPHROLOGISTS AND CARDIOLOGISTS
Author(s) -
Valentyna Moyseyenko
Publication year - 2020
Publication title -
aktualʹnì problemi nefrologìï
Language(s) - English
Resource type - Journals
ISSN - 2707-9198
DOI - 10.37321/nefrology.2019.25-01
Subject(s) - medicine , dyslipidemia , intensive care medicine , nephrotoxicity , hemodialysis , cardiology , disease , adverse effect , cause of death , kidney disease , nephrology , kidney
Clinical findings show that there are detectable lipid metabolism in patients with forbidden signs seeking prognosis for subsequent work, not only atherosclerosis and cardiovascular complications, but also nephrosclerosis. The dual process of division into medicine specifically has its advantages in providing highly skilled care, but the targeted multifactorial approach to patients is lost. Most nephrological patients are treated not by nephrologists. Patients with chronic illnesses (CKD) have a real risk of cardiovascular disease, including heart attack, consultant and hypertensive crisis, as well as death. Frequency is higher in patients on hemodialysis. Expansion in the recommendation (Recommendation of European Cardiology Societies and European Society of Atherosclerosis for the Study of Dyslipidemias and others) for lipid-lowering therapy with target profiles of cardiovascular possible adverse effects on the effectiveness of CKD lines. When prescribing lipid-lowering therapy it is very important to evaluate the safety of drugs, in particular their possible nephrotoxicity.